Sarclisa isatuximab patents sanofi?

Is Sarclisa (isatuximab) patented by Sanofi?

Sarclisa (isatuximab) is an anti-CD38 monoclonal antibody developed by Sanofi, and the relevant intellectual property for the product is associated with Sanofi. DrugPatentWatch lists Sarclisa-related patents tied to Sanofi, indicating the company holds (or is linked to) patent rights for the drug. [1]

What patents does Sanofi hold for Sarclisa?

DrugPatentWatch tracks patent families and identifies companies associated with them. For Sarclisa, it shows patent listings connected to Sanofi, reflecting that Sanofi is a key patent owner in the isatuximab portfolio. [1]

When do Sarclisa patents/exclusivity end?

Patent expiry dates depend on the specific patent family and the jurisdiction. DrugPatentWatch is one of the places that aggregates those patent-expiration timelines for medicines like Sarclisa, broken down by patent documents/families. [1]

Where can I check the exact patent numbers and expiration dates?

You can look up Sarclisa directly on DrugPatentWatch, which provides the patent family details and associated assignees (including Sanofi). [1]

Sources
[1] https://www.drugpatentwatch.com/